R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research
Arnaud Roth,Nicola Fazio,Roger Stupp,Stephen Falk,Jürg Bernhard,Piercarlo Saletti,Dieter Köberle,Markus Borner,Kaspar Rufibach,Rudolf Maibach,M. Wernli,Martin Leslie,Rob Glynne-Jones,Lukas Widmer,Matthew T. Seymour,Filippo de Braud +15 more
TL;DR: Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting, and global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.
Journal ArticleDOI
Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
Giovanni Martinelli,Shu Fang Hsu Schmitz,Urs Utiger,Thomas Cerny,Urs Hess,Simona Bassi,Emmie Okkinga,Roger Stupp,Rolf A. Stahel,Marc Heizmann,Daniel A. Vorobiof,Andreas Lohri,Pierre-Yves Dietrich,Emanuele Zucca,Michele Ghielmini +14 more
TL;DR: An important proportion of patients with follicular lymphoma experienced long-term remission after prolonged exposure to rituximab, particularly if they had no prior treatment and responded to rITUXimab induction.
Journal ArticleDOI
Phase II Study of Imatinib in Advanced Chordoma
Silvia Stacchiotti,Alessandra Longhi,Virginia Ferraresi,Giovanni Grignani,Alessandro Comandone,Roger Stupp,Alexia Bertuzzi,Elena Tamborini,Silvana Pilotti,Antonella Messina,Carlo Spreafico,Alessandro Gronchi,Paola Amore,Vincenza Vinaccia,Paolo G. Casali +14 more
TL;DR: This largest phase II study in chordoma confirms anecdotal evidence that imatinib has antitumor activity in this orphan disease, and therefore, it is worth further investigation.
Journal ArticleDOI
Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Eric Raymond,Alba A. Brandes,Christian Dittrich,Pierre Fumoleau,Bruno Coudert,Paul Clement,Marc Frenay,Roy Rampling,Roger Stupp,Johan M. Kros,Michael Heinrich,Thierry Gorlia,Denis Lacombe,Martin J. van den Bent +13 more
TL;DR: In the dose range of 600 to 1,000 mg/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas.
Journal ArticleDOI
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.
Matthias Preusser,Robert C. Janzer,Jörg Felsberg,Guido Reifenberger,Marie-France Hamou,Annie-Claire Diserens,Roger Stupp,Thierry Gorlia,Christine Marosi,Harald Heinzl,Johannes A. Hainfellner,Monika E. Hegi +11 more
TL;DR: The usability of MGMT immunohistochemistry (IHC) as a clinical biomarker is clarified and postoperative chemoradiotherapy benefits in glioblastoma multiforme patients are confirmed.